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Summary: Ubiquitination is a post-translational modification process
that regulates several critical cellular processes. Ubiquitination is
orchestrated by the ubiquitin proteasome system (UPS), which consti-
tutes a cascade of enzymes that transfer ubiquitin onto protein sub-
strates. The UPS catalyzes the destruction of many critical protein
substrates involved in cancer pathogenesis. This review article focuses
on components of the UPS that have been demonstrated to be deregu-
lated by a variety of mechanisms in hematologic malignancies. These
include E3 ubiquitin ligases and deubiquitinating enzymes. The pros-
pects of specific targeting of key enzymes in this pathway that are criti-
cal to the pathogenesis of particular hematologic neoplasia are also
discussed.
Keywords: ubiquitin-proteasome system, hematologic malignancy, E3 ligase, deubiqu-
itinases
The ubiquitin proteasome system
The ubiquitin proteasome system (UPS) is the major degra-
dation machinery that controls the abundance of critical cel-
lular regulatory proteins through a stepwise cascade
consisting of a ubiquitin activating enzyme or UBA (E1),
ubiquitin conjugating enzymes or UBC (E2), and ubiquitin
ligase (E3) enzymes. The ubiquitin ligases are terminal
enzymes that activate and transfer ubiquitin through a thio-
ester linkage for ultimate transfer of ubiquitin to the
e-amino group of a lysine (K) residue on the substrate or
the amino-terminus of a polypeptide (1, 2). After the link-
age of ubiquitin to the protein substrate, a polyubiquitin
chain is usually formed in which the C-terminus of each
ubiquitin unit is linked to a specific lysine residue (most
commonly Lys48) of the previous ubiquitin if the substrate
is destined for degradation. Fig. 1 illustrates a schematic of
the series of reactions mediated by the cascade of enzymes
in the ubiquitin-proteasome system for degradation of a tar-
get substrate. In humans, there are two E1 proteins, approx-
imately 30 E2 proteins, and hundreds of E3 ligases (3, 4).
The E3 ligases confer substrate specificity to the UPS. The E3
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ubiquitin ligases regulate many biological processes through
timely ubiquitination and degradation of many cellular pro-
teins responsible for gene transcription/repression, receptor
endocytosis, intracellular trafficking, and response to extra-
cellular signals, cell cycle progression, and apoptosis (5, 6).
Perturbation of the timely turnover of regulatory proteins
disturbs the intricate balance of signaling pathways and
ensuing cellular homeostasis contributing to the multistep
process of malignant transformation and tumorigenesis. In
this context, the involvement of E1 in cancer has not been
described, and only a few reports have linked E2 deregula-
tion to cancer development. However, increasing evidence
indicates that deregulation of E3 ligase often results in
development of several types of malignancies including
hematologic malignancies (4, 7). In this review, we discuss
the spectrum of E3 ligases whose substrate targeting func-
tions are noted to be deregulated by multiple mechanisms
in hematopoietic malignancies.
Ubiquitin ligases may exist as multi-subunit complexes or
as a single protein unit, and they may possess one or more
critical domains that facilitate ubiquitination such as RING
domain (really interesting new gene), HECT domain (homol-
ogous to E6-AP carboxy-terminus), or U-box domain (8).
Hence, based on structural configuration and subunit compo-
sition these ligases are classified into several groups such as
HECT-type, single RING-type and multi-subunit RING type
such as SCF-type (Skp1-Cullin 1-F box protein), ECV type,
APC/C (anaphase-promoting complex/cyclosome), and
Cullin4 type (9). While, RING and U-box domain containing
E3 ligases act as a scaffolding protein to recruit substrate and
E2 enzymes in close proximity for ubiquitin transfer, HECT
type E3 ligases receive ubiquitin from an E2 enzyme and can
directly catalyze the conjugation of the ubiquitin molecule
onto the substrate protein. Fig. 2 depicts the schematic repre-
sentation for the mechanism of ubiquitin transfer from an E2
enzyme to substrate among multi-subunit RING type, single
subunit RING type and HECT type E3 ligases.
E3 ubiquitin ligases deregulated in hematologic
malignancies
Many ubiquitin ligases have been implicated in the patho-
genesis of hematologic malignancies (5, 10–19). Aberrant
proteolysis of important regulatory proteins whose precise
and timely function is required for successful progression of
cell division cycle, transcriptional regulation, DNA damage
response and apoptosis significantly contribute to neoplastic
transformation (4, 20–23). Based on the functional effects
conferred by degradation of critical substrates, E3 ligases
have been assigned functions as oncogenes or tumor sup-
pressor (9, 24). However, some of E3 ligases switch their
function as oncogene or tumor suppressor based on context,
timing, localization, and cell lineage (24). Many ubiquitin
ligases are mutated, overexpressed or deleted in hematologic
malignancies contributing to the pathogenesis of the diseases
through accumulation or excessive degradation of their sub-
strates which perform critical functions that regulate proper
hematopoietic cell growth and differentiation. Fig. 3 illus-
trates the E3 ligases and deubiquitinases (DUBs) that harbor
genetic aberrations in hematologic cells.
These E3 ligases along with associated E2 enzymes
function as multisubunit complexs. The cullin-RING E3
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Fig. 1. Illustration of the series of reactions mediated by the
cascade of enzymes of the ubiquitin-proteasome system. Initially, in
the ubiquitin activation reaction, the 76 amino acid ubiquitin molecule
is activated by its transfer to E1 enzyme in an ATP-dependent manner.
In the next step, this activated ubiquitin is then transferred from E1
enzyme to the E2 enzyme in ubiquitin conjugation reaction. The E2
enzyme then interacts with E3 ligase and come in close proximity of
substrate allowing for the ubiquitin transfer to the substrate. This
process is repeated several times with the Lys of the ubiquitin protein
serving further as the substrate to generate polyubiquitin chain. Once a
chain of K48 linked four or more ubiquitin molecule is formed onto
the substrate protein, the substrate is then targeted for degradation by
the 26S proteasome. However, before undergoing degradation by 26S
proteasome, the polyubiquitination signal from the substrate can be
reversed by deubiquitinase enzyme thereby protecting substrate from
degradation. The E3 ligases and deubiquitinase enzymes are important
because they mediate target substrate specificity during this process of
proteasomal degradation.
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ubiquitin ligase complexs (CRLs) comprises the largest
known class of multicomponent-RING E3 ligases and target
a wide array of substrates critical for cellular homeostasis
(Fig. 2). CRLs are composed of a cullin protein scaffold that
binds a RING protein to recruit an E2 protein at one end as
well as utilize specific adapters that associates with distinct
class of substrate receptors. Substrate receptors interact with
and present substrates to the E2-CRL complex for polyubiq-
uitination followed by degradation through 26S proteasome.
Among all cullin-RING complexes, Cullin1-mediated SCF
complexes are most extensively characterized.
The SCF type ubiquitin ligase is a multiprotein complex
with three core components: RBX1 (Ring finger protein 1),
CUL1 (Scaffold protein), and SKP1 (adapter protein), and
one variable component F box protein (substrate receptors)
that associates with a complex via binding to SKP1 through
its F box motif. Substrate selection is generally achieved
through interaction of the substrate-interaction domain of F
F box 
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Fig. 2. The complex composition and mechanism of action of E3 ligases that are reported to be genetically altered in hematologic
malignancies. (A) SCF (SKP1-CUL1-F-box protein) type E3 ligase complex. The SCF [SKP1 (S phase kinase associated protein 1) CUL1 (Cullin 1)
RBX1 (Ring box 1)] core complex recruits substrates through interchangeable substrate specific F box proteins. RBX1 binds to the E2 enzyme
while F box protein binds to the target substrate. (B) c-CBL E3 ligase complex. CBL is a multi-domain protein. A tyrosine kinase-binding domain
(TKBD) is connected to the RING domain via a linker-helix region. The RING domain binds the E2 enzyme and TKBD bind the substrate. (C)
HECT type E3 ligase complex. In case of (A) and (B) which are RING type E3 ligase, the E2 enzyme interacts with E3 ligase to come in close
proximity of substrate which has also interacted with E3 ligase at the different region and transfer ubiquitin molecule to the substrate. While in
case of HECT E3 ligase, the E2 enzyme transfer ubiquitin molecule to E3 ligase and then E3 ligase directly transfer the ubiquitin molecule onto
the target substrate.
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Fig. 3. Illustration of different E3 ubiquitin ligases and deubiquitinases that are reported to harbor genetic aberrations altering their
function in hematologic malignancies. In this illustration, the relevant ubiquitin ligases and deubiquitinases that are genetically altered through
mutation/deletion or overexpression are shown along the line of the hematologic cell maturation program.
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box protein with a target protein destined for degradation.
So far, 69 F box proteins have been identified in humans,
and they can be classified into three categories: those with
WD 40 repeats (FBXW), leucine-rich repeats (FBXL), or
other domain-containing proteins (FBXO) (25, 26). The
SCF complex utilizes these 69 different F box proteins as
substrate receptors to form 69 distinct SCF complexes. The
following section highlights the selected E3 ligase compo-
nents that are reported to be genetically altered and thus
contribute to the development of hematologic malignancies.
First, the hematologic malignancies harboring genetic aber-
rations within multi-subunit RING-type SCF E3 ligase sub-
strate receptor F box proteins are discussed starting from
FBXW type, FBXL type and FBXO type. Next, hematologic
malignancies harboring genetic aberrations in single subunit
RING type CBL E3 ligases are discussed. Finally, the hemato-
logic malignancies harboring genetic aberration within
HECT type E3 ligases are discussed (Table 1).
Fbw7
Fbw7 is an F box-containing protein that has F box domain
interacting with the E3 ligase complex through SKP1
(adapter protein) and eight WD40 repeats that interact with
phosphorylated target substrates. Frequent inactivation of
Fbw7 by deletions or point mutations occurs in neoplasia of
diverse hematologic malignancies such as T-cell acute lym-
phocytic leukemia (T-ALL) and B-cell acute lymphoblastic
leukemia (B-ALL) (16, 17, 19, 27). Specifically, the most
frequent Fbw7 mutations are identified in T-ALL (approxi-
mately 30%) and cholangiocarcinomas (approximately 35%)
(28). Commonly the missense mutations of Fbw7 occurring
at R465C, R479Q, and R505C within WD40 repeats 3 and
4 (from Fbw7a) diminish its capacity to recruit substrates to
the E3 ligase complex by loss of interaction (19). Fbw7
substrates have been demonstrated to play critical roles in
cell cycle progression, differentiation, and metabolism and
function as dominant oncogenes. Therefore, Fbw7 is
believed to function as tumor suppressor due to the negative
regulation of its substrate oncoproteins. Collectively, the
studies indicate that Fbw7 mutations can disrupt targeted
proteolysis of substrates responsible for cell growth and pro-
liferation promoting oncogenesis.
Fbxw10
Another WD40 repeat domain containing F box protein,
Fbxw10, also known as HREP, Fbw10, SM25H2, and
Table 1. Genetic aberration of E3 ligases and deubiquitinases identified in hematologic malignancies
Genetic aberration identified Malignancy associated References
Ubiquitin ligases
Fbxw7 Trisomy, Insertion/Deletion (Indel), Frame shift, Missense including
R465H/C, R479Q, R505C/L, H420Y, H470P
T-ALL, B-ALL, CLL (16, 17, 19, 27, 165)
Fbxw10 Missense, Nonsense and Frame shift mutations including R318N,
R416* and K966fs
T-PLL (94)
Fbxl1 (Skp2) Overexpression, gene amplification Various NHL (14, 30, 31)
Fbxl2 Expression down-regulation AML, ALL (10)
Fbxo9 Overexpression and copy number gain MM (45)
Fbxo10 Frame shift mutations, Expression down-regulation including R44H,
V762L and R825W missense and
DLBCL (11)
Fbxo11 Frame shift mutations and Deletions including Y122C, D665-675fs,
D333fs, K631Q/N and G600E
BL and DLBCL (12)
Smurf2 Expression down-regulation BL and DLBCL (18)
UBR5 Insertion/Deletions, Frame shift mutations, Missense, and splice site
mutations including W2725* and H1932P
MCL (15)
c-CBL Deletions, splice acceptor site mutations and Missense mutations
including Y371H/S, C401S, R420Q/P, C384Y, C404Y/S, F418S,
L370_Y371 ins L, L399V, C416W, and G415S
MDS, MPN (CMML, JMML),
CML, ALL, AML, MDS,
and systemic mastocytosis
(13, 55, 56, 62, 166–169)
Deubiquitinase
USP9X Overexpression FL, DLBCL and MM including
relapsing AML and ALL
(115–117)
CYLD Deletions and expression downregulation cHL and T-ALL (123, 170)
A20 Deletions, Frame shift mutations, Promoter hyper-methylation and
Nonsense mutations including 532*, 750*, W85*, E452*, and
Missense mutations including A753T, E751K, Q737K, and M788I
DLBCL, MCL, MZL, MALT,
HL, and T-ALL
(133–141, 171)
c-HL, classical Hodgkin’s lymphoma; NHL, non-Hodgkin’s lymphoma, FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; MCL, mantle
cell lymphoma, MM, multiple myeloma; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; MDS, myelodysplastic syndrome; MPN, myelo-
proliferative neoplasm, CMML, chronic myelomonocytic leukemia; JMML, juvenile myelomonocytic leukemia; CML, chronic myelogenous leukemia;
T-PLL, T-cell pro-lymphocytic leukemia; SS, Sezary syndrome.
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SM2SH2, has been reported to harbor frame shift and non-
sense mutations in T-cell prolymphocytic leukemia (T-PLL)
(29). Overall, very little is known about this F box protein’s
function and the biological consequences of its inactivation.
Identification of substrates targeted by this F box protein
may further provide significant insights on its role in the
pathogenesis of T-PLL.
Fbxl1
The Fbxl1, also commonly known as S-phase kinase-associ-
ated protein 2 (SKP2), is a leucine-rich domain containing F
box protein. SKP2 overexpression was associated with poor
prognosis in human lymphoma patients (30, 31). The onco-
genic potential of SKP2 has also been shown in transgenic
mouse models of T lymphoid lineage where expression of
SKP2 with N-ras developed T-cell lymphoma with shorter
latency and decreased survival (14). SKP2 is a major regula-
tor of cell cycle progression through degradation of cell
cycle intermediates. The development and progression of
several types of malignancies are fundamentally associated
with deregulated cell cycle control. Cell cycle progression is
precisely regulated by timely synthesis and degradation of
cell cycle regulatory proteins: cyclin-dependent kinases
(CDK1, CDK2, CDK4, and CDK6), their essential activating
coenzymes, the cyclins (cyclin A, B, D, and E), the CDK-
inhibitory proteins (CDKIs), and their associated signaling
networks that control their function via post-translational
modifications. The abundance of these intermediates during
the different phases of cell division cycle is tightly con-
trolled by UPS (4, 32).
Cell cycle progression is principally driven by cyclins and
their respective cyclin-dependent kinase (CDK) complexes in
different phases of cell cycle. Cyclin-dependent kinase inhib-
itors (CKIs) are the critical regulators of cyclin-CDK activi-
ties. CKIs function by inhibiting CDK activity and
promoting cell cycle arrest and/or delaying the response to
anti-mitogenic stimuli. These CKIs fall into two families: the
INK4 inhibitors and CIP/KIP inhibitors. There are four
known INK4 family members: p16INK4A, p15INK4B,
p19INK4D, and p18INK4C. The three mammalian CIP/KIP
CKIs- namely p21CIP1, p27KIP1 and p57KIP2 play different
role in cell cycle regulation (32, 33). SCFSKP2 E3 ligase com-
plex targets all three CKIs: p21CIP1, p27KIP1, and p57KIP2 at
different stages of cell cycle for degradation (34–39). How-
ever, p27KIP1 seems to be the principal target of SKP2 as the
prominent phenotypes apparent in SKP2/ mice including
nuclear enlargement, polyploidy and an increased number
of centrosomes, that are linked to over-replication of
chromosomes and centrosomes. These phenotypic aberra-
tions disappear in Skp2/ p27/ double mutant mice
(40, 41). Degradation of p27KIP1 by SKP2 would promote
cell transition from G1 to S phase, and therefore increased
expression of SKP2 would result in a failure to regulate the
G1/S checkpoint. Since SKP2 targets p27KIP1 and other CKIs
for degradation, it can be considered an oncogene. In addi-
tion to CKIs, SKP2 also targets p130, cyclin A, cyclin D1,
free cyclin E, ORC1, CDK9, MYC, Myb, SMAD4, RAG2,
UBP43, FOXO1, and papillomavirus E7 protein, suggesting
its crucial role in governing many key cellular processes
(42).
Fbxl2
Similar to Fbxl1, another Fbxl family member Fbxl2 E3
ubiquitin ligase recruits cyclin D2 for ubqiuitination and
degradation in normal B lymphocytes and leukemic B cells.
An inverse correlation has been observed between Fbxl2 and
cyclin D2 in primary samples of human acute myeloid
leukemia (AML) and acute lymphoid leukemia (ALL) (10).
Fbxl2 activity results in cell cycle arrest in G0 and subse-
quent apoptosis. The anti-proliferative activity of Fbxl2 in
B-cell lymphoma and leukemia suggests a role in hemato-
logic malignancies.
Fbxo7
The F box-containing proteins in which the substrate inter-
action domain is neither a WD40 nor leucine-rich repeat are
designated as Fbxo (other domain) proteins. Among these,
genetic ablation of Fbxo7 in mice has been reported to
increase pro-B cell and pro-erythroblast populations (43).
Furthermore, the expression of Fbxo7 in hematopoietic pro-
genitor cells cooperates with p53 loss to promote T-cell
malignancy suggesting its oncogenic potential (44). Hence,
identification and validation of additional substrates of
Fbxo7 may elaborate its role in the pathogenesis of hemato-
logic malignancies.
Fbxo9
Fbxo9 is an other domain containing F box protein. Its
expression has been reported to be approximately fivefold
elevated in multiple myeloma (MM) cells. In a study exam-
ining a cohort of 180 MM patients, the neoplastic cells in
30% of cases showed overexpression of Fbxo9 (45). Notably,
the UPS has been recognized as a promising therapeutic
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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target in multiple myeloma, the second most common he-
matologic malignancy in western countries (46–48). Indeed
the proteasome inhibitor bortezomib has gained utility as
first line treatment for this disease (46, 47). High expression
level of Fbxo9 correlates with higher progression-free sur-
vival and better prognosis in MM patients treated with bort-
ezomib (45). This suggests that Fbxo9 may be a useful
marker to predict clinical response to proteasomal inhibi-
tion. Fbxo9 regulates mTOR signaling toward cell survival
and growth via mTORC1 specific degradation of Tel2 and
Tti1 in multiple myeloma. Identification of Fbxo9 target
substrates are limited and required further exploration.
Fbxo10
The Fbxo10 is other domain containing F box protein. The
Fbxo10 mRNA levels are decreased in germinal center (GC)
derived (approximately 33%) and activated B cell (approxi-
mately 46%) type of diffuse large B-cell lymphomas
(DLBCL) patient samples as compared to naive B cells (11).
Moreover, frameshift and missense mutations have been
observed in the Fbxo10 gene in DLBCL (11). These mutations
significantly compromise the ubiquitin ligase function of
Fbxo10. Specifically, mutation at F box domain (R44H)
abrogates the capacity of Fbxo10 to interact with Skp1 adap-
ter protein to form a functional SCF E3 ligase complex. Fur-
ther mutations in the CASH domain of Fbxo10 (V762L and
R825W), which is responsible for substrate interaction, par-
tially compromise Fbxo10 function (11). Fbxo10 mutants
were less toxic than wildtype presumably by impairing its
tumor suppressor function. Fbxo10 mutations identified in
DLBCLs are heterozygous and hypomorphic in nature, indi-
cating that Fbxo10 functions as a haploinsufficient tumor
suppressor. However, absence of Fbxo10 homozygous
mutations suggests that its activity may be critical for devel-
opment of lymphoma. DLBCL are the most common form
of B-cell lymphoma accounting for approximately 30–40%
of newly diagnosed non-Hodgkin’s lymphoma (49). To
fully understand the critical balance between the level and
activity of Fbxo10 required for normal physiology but not
for lymphoma development, it will be important to under-
stand how the level of this protein is regulated and further
what are the other substrates and cellular pathways that are
controlled by Fbxo10-mediated proteasomal degradation.
Fbxo11
Fbxo11, another family member of Fbxo group, is targeted
for deletion and mutation in multiple DLBCL cell lines and
primary samples (50). These deletions were largely
monoallelic, suggesting a haplo-insufficient tumor suppres-
sor function for Fbxo11. The mutations identified, altered
the subcellular localization of protein. Most of the mutations
have been shown to target the substrate binding CASH
domain rendering the Fbxo11 functionally compromised.
Specifically, in OCILY1 (germinal center B-like DLBCL-
derived) cells, Fbxo11 gene locus sequencing revealed a point
mutation in the CASH domain. Furthermore, analysis of
approximately 100 primary DLBCL samples revealed six
sequence variants that were shown to be somatic by analysis
of paired normal DNA. Five of the six identified mutations
were in the CASH domain and one of these five mutations
was a frameshift mutation generating a functionally defec-
tive Fbxo11 protein. Most of the Fbxo11 alterations were
hemizygous deletions (14.8%, n = 27) and inactivating mis-
sense or frame shift mutations (14.3%, n = 7) in DLBCL cell
lines, and mutations (4%, n = 100) in primary DLBCL sam-
ples (12). Moreover, gene copy analysis by two independent
studies also report Fbxo11 deletions (8.7%, n = 69) in
human DLBCLs samples analyzed (50). Since Fbxo11 muta-
tions are often identified in substrate recruitment domain, it
is conceivable that Fbxo11 deletions or mutations may con-
tribute to DLBCL pathogenesis by stabilizing substrate onco-
proteins critical for disease progression. Identification of
novel Fbxo11 substrates in germinal center-derived B cells
may provide significant insight onto the role of Fbxo11 in
B-cell malignancy.
c-CBL
Originally identified as cellular homolog of murine viral
oncogene (v-Cbl), the casitas B-lineage lymphoma (cbl)
family of E3 ubiquitin ligases specifically target receptor
tyrosine kinase-mediated signaling pathways as well as
Akt-PI3K and Ras-Raf-MAPK pathways (51, 52). The
N-terminal regions of Cbl family proteins are highly con-
served and include the tyrosine kinase binding (TKB), RING
finger (RF), and short linker region between these two
domains. The RING finger domain and the linker region
together mediate recruitment of E2 ubiquitin-conjugating
enzymes and thus are essential for the E3 ligase activity of
Cbl proteins (53). Although CBL mutations have been
reported in a variety of myeloid neoplasms, the mutations
are most frequently observed in myelodysplastic syndromes:
myeloproliferative neoplasm (MDS/MPN), including chronic
myelomonocytic leukemia (CMML) (approximately 15%),
juvenile myelomonocytic leukemia (JMML) (approximately
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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17%), and atypical chronic myeloid leukemia (approxi-
mately 5%) (54–62). Further somatic c-CBL mutations have
also been reported in acute lymphoblastic leukemia (ALL)
(63). Most c-CBL mutations in MPNs such as AML are iden-
tified within the linker/RING finger domains, and are pre-
dicted to abrogate the interaction of c-CBL with E2
conjugating enzymes, and thus impair the E3 ligase activity
of the molecule (62). The tumor-derived mutations in lin-
ker/RING domain have shown severely compromised E3
ligase activity when expressed in fibroblast cells (60, 62).
Smurf2
Smurf2 (Smad ubiquitination regulatory factor-2) is a HECT
domain type E3 ubiquitin ligase that is involved in the deg-
radation of critical substrates involved in establishment and
functioning of the germinal center reaction. From the pub-
lished microarray data set (GSKE2350) for human primary
B-cell lymphoma samples and normal B cells it was observed
that human primary B-cell lymphomas (DLBCL, BL, and FL)
express lower levels of Smurf2 as compared to normal B
cells (18). Smurf2-deficient mice exhibit increased prolifera-
tion of splenic B cells and develop GC or post GC-derived
B-cell lymphomas suggesting a tumor suppressor function
for Smurf2 (18). Smurf2 is also an important regulator of
senescence and in the absence of apoptosis; senescence
becomes prominent tumor suppressor mechanism to over-
come oncogenic activities within cells. However, Smurf2-
deficient cells bypass the senescence program and undergo
prolonged cell proliferation in splenic B cells providing a
favorable background for evolution to malignant lymphoma
(64). Genetic analysis has not observed a deletion at Smurf2
locus in human DLBCL, suggesting a possible role for epige-
netic or post-transcriptional regulation of Smurf2 deficiency
in human lymphomagenesis. DLBCL and BL patients having
low expression levels of Smurf2 exhibit poorer prognosis
than patients having higher Smurf2 levels. Interestingly, the
level of Smurf2 does not correlate with follicular lymphoma
patient survival suggesting that Smurf2 expression can spe-
cifically be a valuable prognostic marker for DLBCL and pos-
sibly BL patients (18).
UBR5
UBR5 is a HECT domain type E3 ubiquitin ligase that plays
a critical role in cell cycle progression and DNA damage
response pathways (65, 66). UBR5 has been found to be
recurrently mutated in mantle cell lymphoma (MCL)
characterized primarily by the recurrent t(11,14)(q13;q32)
aberration resulting in constitutive overexpression of cyclin
D1 (15). Majority of UBR5 mutations (61%) result in frame
shifts in or around exon 58 and are predicted to generate
functionally defective UBR5 protein. The consequences of
defective UBR5 and its ubiquitination substrates responsible
for progression of MCL are yet to be determined and offer
an interesting avenue for identification of novel substrates
that can be exploited for therapeutic targeting.
Deregulated E3 ubiquitin ligase substrates that are
implicated in hematologic malignancies
There are many key cellular players involved in cell cycle
regulation, transcriptional control, or epigenetic modulation
of gene expression that participate in the pathogenesis of
hematologic malignancies. Often, the abundance and activity
of these regulators are controlled at the post-translational
level by the UPS and aberrant turnover of these proteins due
to defect in degradation signal or mutation/deletion/aber-
rant expression of degradation machinery may facilitate pro-
gression to outright malignancy through inappropriate
turnover of substrates critical for proper hematopoiesis. The
following section highlights the selected critical regulators
of hematopoiesis which are regulated at post-translational
level by the UPS.
EZH2
EZH2 (enhancer of zeste homolog 2), a SET domain-con-
taining histone methyltransferase, is a critical enzymatic sub-
unit of the polycomb repressive complex 2 (PRC2) which
trimethylates histone H3 (H3K27) to mediate gene repres-
sion (67). The activity of EZH2 largely depends upon
assembly of core complex involving other PRC2 compo-
nents, EED (embryonic ectoderm development) and SUZ12
(suppressor of zeste 12) (68). Appropriate level and activity
of EZH2 is critical for normal development because EZH2
deletion is lethal in early embryonic development and EZH2
knockout embryos fail to implant and undergo gastrulation
(69). In lineage-specific stem cells of diverse origin, EZH2
and cooperating proteins regulate the proper coordination
of differentiation and proliferation (70–72). EZH2 is
expressed at high levels in human germinal center B cells,
and its expression levels fluctuate according to maturation
state of B cells. EZH2 expression is high in germinal center
B cells to maintain the germinal center phenotype long
enough to mediate multiple rounds of division and somatic
hypermutation for antibody affinity maturation and decline
once B cells exit the germinal center (73, 74).
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
230 Immunological Reviews 263/2015
Sahasrabuddhe & Elenitoba-Johnson  UPS and hematologic malignancies
Somatic mutations, overexpression, and hyperactivation
of EZH2 have been reported in the pathogenesis of several
malignancies (71). Genome-wide sequencing studies
recently identified heterozygous somatic and recurrent
gain-of-function mutations targeting EZH2Y641 occurring
most frequently in germinal center derived follicular and
aggressive diffuse large B-cell lymphoma. This mutation is
associated with H3K27me3 hyper-activation promoting
lymphomagenesis (73–76). These mutations have been
reported to alter the enzymatic activity of EZH2 (with
preference for trimethylation of H3K27) as well as its sta-
bility, resulting in a protein with prolonged half-life.
SCFbTrCP E3 ubiquitin ligase recognizes Y641 phosphory-
lated EZH2 for polyubiquitination and degradation by 26S
proteasome system (77). The mutations at Y641 compro-
mise the phosphorylation of EZH2 by Jak2 tyrosine kinase
and ensuing recognition by SCFbTrCP E3 ubiquitin ligase
rendering long-lived protein with attendant increase in
H3K27 trimethylation activity. Usually bTrCP recognizes a
conserved phospho-degron DpSG(X)2-5pS through its criti-
cal residues R474 residing in its 7th WD repeat region
(78). It has been demonstrated that the SCFbTrCP R474A
mutant is unable to recognize EZH2 adding another layer
of complexity to post translational regulation of EZH2
(77). Therefore, further studies on the detailed molecular
mechanism of EZH2 degradation by bTrCP and involve-
ment of secondary signaling including the role of Jak2
kinase in the context of B-cell lymphoma pathogenesis at
germinal center microenvironment may provide potential
new therapeutic opportunities against EZH2 driven lym-
phomagenesis.
BCL6
BCL6 is a transcriptional repressor required to maintain
germinal center reaction very much like EZH2 and its dereg-
ulation has been implicated in the pathogenesis of human
B-cell lymphoma (79). BCL6 controls the germinal center
program through transcriptional repression of a variety of
genes to prevent premature activation and differentiation of
B cell toward memory and plasma cells (80–88). Chromo-
somal translocations involving BCL6 (approximately 40%)
and overexpression of BCL6 through promoter hypermuta-
tion (approximately 15%) have been identified in aggressive
diffuse large B cell lymphomas (DLBCL), the most common
lymphoma in adulthood (12, 89–92). Apart from promoter
hypermutation or chromosomal translocation, proteasomal
degradation of BCL6 is another mechanism of its regulation
within germinal center (12). BCL6 is targeted for
ubiquitination and degradation by SCFFbxo11 (12). SCFFbxo11
mediated degradation of BCL6 regulates its optimal required
levels/activity in germinal center B cell and during germinal
center exit for the generation of memory B cell and plasma
cells. Fbxo11 silencing in a DLBCL cell line promotes tumor-
igenesis in immunodeficient mice and its reconstitution sup-
presses tumor growth. Frequent deletion and mutations of
Fbxo11 have been identified in multiple DLBCL cell lines
and primary DLBCL patient samples, and loss of Fbxo11 has
been observed to promote stability of BCL6 protein. Fbxo11
mutants displayed an impaired ability to trigger BCL6 degra-
dation and thus potentially contributing to lymphomagene-
sis through BCL6 stabilization. However, the secondary
signaling pathways controlling Fbxo11 mediated BCL6 deg-
radation and maturation stages of GC when BCL6 levels are
controlled by degradation machinery are yet to be delin-
eated.
Notch signaling components
Notch signaling plays a critical role in lineage commitment
during lymphocyte development and further in oncogenic
transformation (93). Hyperactivation of Notch signaling has
been implicated in several hematologic malignancies includ-
ing T-cell acute lymphoblastic leukemia (T-ALL), B-chronic
lymphocytic leukemia, and splenic marginal zone lym-
phoma (94–97). Further, adding another layer of complex-
ity to lineage specific functions, Notch signaling evokes
tumor suppressor activity in myeloid malignancies (98). It
therefore appears that oncogenic or tumor suppressor activi-
ties of Notch signaling pathways are highly context depen-
dent. Notch signaling is significantly regulated by the UPS,
and deregulation of Notch1 signaling due to activating
mutations in Notch1 receptors that impair its recognition
and degradation by SCFFbxw7 E3 ligase has been reported to
promotes lymphomagenesis (16, 19). Notch1-Fbw7 axis is
very well characterized, however the C-terminal PEST
domain of Notch is highly conserved among different
Notch proteins. Two independent studies identified Notch2
mutations in splenic marginal zone lymphoma (SMZL)
patients using whole genome sequencing (94, 95). The
mutational frequency ranged from 21% to 25% of cases,
targeting Notch2 as the most mutated gene in both of these
studies. Most of the identified mutations targeted the con-
served C terminal PEST region predicted to be docking sites
for E3 ligase(s) involved in the proteasomal turnover of the
Notch2 protein (94, 95). It is tempting to speculate that
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frame shift and deletion mutations targeting PEST domain
may increase the stability of mutant Notch2 protein with
attendant hyperactivity directed toward progression of
SMZL. Further studies are required to establish the mecha-
nism of hyperactivation of Notch signaling induced by the
Notch2 mutations and identification of possible additional
E3 ligase machinery that might participate in Notch2 post-
translational regulation.
NFjB signaling components
Nuclear factor-jB (NFjB) is a structurally and evolutionally
conserved family of transcription factors that are critical for
the development of T and B lymphocytes (99). Activation
and regulation of NFjB transcription factors is highly
dependent on the developmental stage and the initiating
signal. NFjB family is consists of five structurally related
activators (RelA or p65, RelB, c-Rel, p50, and p52) and five
inhibitory proteins [p100, p105, and Inhibitor of jB (IjBa,
IjBb, and IjBe)] (100). The activators are synthesized as
mature products and harbor C-terminal transactivation
domains. The p50 and p52 activators are products of prote-
olytic processing of long precursors p105 and p100, respec-
tively. The NFjB activators share a 300 amino acid Rel
homology domain (RHD) that regulates the binding, dimer-
ization and nuclear localization of active NFjB transcription
factor. The five inhibitors possess ankyrin repeat domains
(ARDs) that associate with RHDs of NFjB members to exert
inhibitory activity, primarily by sequestering them in the
cytoplasm. NFjB signaling is activated through two princi-
pal pathways; namely the classical and alternate pathway.
Although both pathways show similarity in proteasomal
degradation of inhibitory components of pathway triggering
activation of signaling, the factors such as nature of stimuli,
upstream kinase and inhibitor of jB kinase (IKK) complex
composition, resulting heterodimer of NFjB transcription
factor and identity of the regulated target genes dictates the
pathway type. The classical pathway is triggered by proin-
flammatory cytokines [tumor necrosis factor a (TNFa),
interleukin IL-1b, or ligand of T-cell or the B-cell receptor]
and leads to IjBa degradation following IKKb and NF-jB
essential modulator (NEMO)/IKKc driven phosphorylation,
releasing RelA/p50 heterodimer and are associated with
innate immunity. On the other hand, the alternative path-
way is stimulated by members of TNF cytokine family
(lymphotoxin-b, BAFF, and CD40) and relies on the IKKa
mediated p100 phosphorylation regulated by NIK depen-
dent and NEMO/IKKc independent pathways, releasing
hetero-dimeric transcription factor RelB either associated
with p50 or p52 and these pathways are mainly involved in
adaptive immunity (101). Aberrant activation of NFjB sig-
naling is directly associated with several hematological
malignancies. In this regard, multiple myelomas (MM)
exhibits constitutive activation of NFjB signaling and often
carry a variety of NFjB pathway mutations, most of which
are affecting the pathway upstream of IjB degradation.
Bortezomib, an inhibitor of the 26S proteasome, is used for
the treatment of multiple myeloma which partly prevents
the degradation of NFjB inhibitory proteins and conse-
quently ablates the oncogenic signal triggered by NFjB acti-
vation (47). Success of proteasome inhibitor treatment
reinforced targeted inhibition of other ubiquitin proteasome
components for therapeutic intervention. To this end, the
neddylation inhibitor MLN4924, which blocks the function
of all cullin-RING ubiquitin ligases (CRLs) entered phase I
clinical trial for multiple myeloma and showed effective
blockade of NFjB signaling in multiple myeloma as well as
activated B-cell type diffuse large B-cell lymphoma (102–
105). The E3 ligase activity of CRLs largely depends upon
NEDD8, a 9 kDa ubiquitin like small molecule, modification
on cullin scaffold protein. Neddylation is mediated through
enzymatic cascades much akin to the ubiquitin system and
is initiated by NEDD8 activating enzyme (NAE). Therefore,
inhibition of NAE abrogates NEDD8 modification and con-
sequently compromises the CRL E3 ligase function (106).
Two SCF type E3 ligases, Fbxw1 (bTrCP) and Fbxw7a, have
been implicated in the regulation of the NFjB pathway
(99, 104, 107). bTrCP polyubiquitinates IjBa as well as
p105 for proteasomal degradation while triggering the pro-
teolytic processing of p100 to generate p52, the active com-
ponent of NFjB transcription factor, which directs
activation of canonical as well as non-canonical NFjB sig-
naling (108–110). Fbxw7a is responsible for ubiquitination
and degradation of nuclear p100 and thus favors non-
canonical pathway activation (104). How these two F box-
containing proteins are coordinated for activation of a par-
ticular NFjB pathway and the context at which the specific
E3 ligase activity prevails for canonical or non-canonical
NFjB pathway activation are not yet clearly understood and
need further exploration.
Myc
The Myc family of transcription factors plays pivotal roles in
several critical cellular processes including growth, apoptosis,
and proliferation (111). Overexpression and chromosomal
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translocation mediated hyperactivation of c-Myc oncoprotein
has been observed in large number of hematologic malig-
nancies including Burkitt lymphoma. The c-Myc oncoprotein
also undergoes another layer of regulation through SCFFbxw7
mediated proteasomal degradation. Several mutations identi-
fied in the coding region of c-Myc center around Thr 58
which undergoes phosphorylation by GSK3b and facilitates
recognition and polyubiquitination of c-Myc by Fbxw7 for
degradation (112). Proteasome-mediated degradation of c-
Myc is significantly impaired in Burkitt lymphoma harboring
Thr58 or other mutations critical for Fbxw7-mediated recog-
nition of the transcription factor (112, 113). The counteract-
ing activity of c-Myc as well as v-Jun and Notch-1
ubiquitination (substrates of Fbxw7a) has been shown to be
mediated by the USP28 DUB in colorectal cancer (114).
However, its role in c-Myc driven progression of hematolog-
ic malignancy is not explored and offers a potential avenue
for further studies.
Role of deubiquitinases in hematologic malignancies
The activities of E3 ubiquitin ligases are counteracted by
DUBs, which remove ubiquitin protein from the substrates
and thereby regulate the level and activity of the protein
substrates. Therefore, similar to E3 ubiquitin ligases, dysre-
gulation of DUBs also contributes to the pathogenesis of
hematologic malignancies. However, unlike E3 ligases, the
DUBs and their roles in the progression of hematologic
malignancy have not been explored extensively.
On the basis of their domain structure, DUBs are classi-
fied in to five families: the ubiquitin carboxy-terminal
hydrolases (UCHs), the ubiquitin-specific proteases (USPs),
the ovarian tumor-related proteases (OTUs), the Machado-
Joseph disease protein domain proteases (MJDs), and the
JAB1/PAB1/MPN-domain containing metallo-enzyme (JAM-
Ms). The USPs constitutes the largest family of DUBs with
53 USP genes that are identified in the human genome.
USP9X
USP9X is overexpressed in several B-cell malignancies
including follicular lymphoma, diffuse large B-cell lym-
phoma, and multiple myeloma (115). The overexpression
of USP9X has been significantly associated with poor prog-
nosis for patients with multiple myeloma (115). Patients
overexpressing USP9X had a 5.5-fold greater risk of death
(115). USP9X promotes cell survival, at least in part by
deubiquitination of MCL1, a pro-survival BCL2 family
member. USP9X stabilizes MCL1 protein by removing its
degradative Lys 48-linked polyubiquitin chain. Increased
levels of MCL1 are associated with poor outcome in multi-
ple myeloma (116), relapsing acute myeloid leukemia and
acute lymphocytic leukemia (117). Hence, targeting USP9X
through pharmacologic inhibition might be therapeutically
advantageous against B-cell malignancies associated with
increased expression of USP9X.
USP9X also plays a pivotal role in T-cell proliferation,
cytokine production, and Th (T-helper) cell differentiation
by regulating TCR-induced NFjB signaling (118). Since
USP9X has different target substrates depending upon the
cell type, further studies are needed to gain more insight
into the mechanism of USP9X function and regulation in B
and T-cell signaling. Development of inhibitors of USP9X is
underway and might offer important therapeutic benefit in
hematologic malignancies associated with aberrant activity
of USP9X (119).
CYLD
CYLD, a member of the USP class of DUBs, was originally
identified as a tumor suppressor in familial cylindromato-
sis, a disease characterized by development of multiple
skin tumors mostly on the scalp (120). Tumors were
characterized by loss of heterozygosity, and the majority
of the mutations were clustered at the catalytic domain of
second copy of the gene rendering the protein non-func-
tional (121, 122). Furthermore, CYLD is located on
16q12-13, a region recurrently deleted in cHL and its
expression are decreased in human T-ALL (123, 124).
CYLD is a negative regulator of NFjB signaling and its
loss enhances NFjB signaling following TNF stimulation
(125–127). CYLD also exhibits NFjB independent roles
that may be associated with neoplastic progression includ-
ing regulation of mitotic entry and cytokinesis (128, 129)
and enhancement of cell migration (130, 131). As a nega-
tive regulator of NFjB signaling and having independent
oncogenic function, it is anticipated that CYLD might play
yet undiscovered roles in the pathogenesis of hematologic
malignancies.
A20
A20, also known as TNFa induced protein-3 (TNFAIP3), is
an N-terminal OTU domain-containing ubiquitin editing
enzyme with dual function as E3 ubiquitin ligase and DUB
and primarily attenuates NFjB-mediated proinflammatory
signaling (132). It contains seven zinc finger (ZnF) domains
in its C-terminus, including ZnF4 that functions as an E3
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Immunological Reviews 263/2015 233
Sahasrabuddhe & Elenitoba-Johnson  UPS and hematologic malignancies
ligase, and an OTU domain for deubiquitination embedded
in its N terminus (132, 133). A20 overexpression inhibits
NFjB activation in response to different stimuli. It is known
to function as tumor suppressor in several types of hemato-
logic malignancy and is inactivated by deletions, promoter
hypermethylation, frame shift and nonsense mutations that
result in impaired protein function (133–139). Biallelic
mutations in the coding region of A20 have been identified
in approximately 30% of B-cell lymphomas, including dif-
fuse large B-cell lymphoma, mantle cell lymphoma, mar-
ginal zone lymphoma of mucosa-associated lymphoid tissue,
and Hodgkin’s lymphoma (133–139). A20 inactivation by
any mechanism contributes to lymphoma progression by
rendering unchecked and abnormally prolonged NFjB activ-
ity resulting in decreased apoptosis and increased cell sur-
vival (133–139). A20 inactivation is also observed in T-cell
malignancies including T-ALL and Sezary syndrome (140,
141). High resolution array comparative genomic hybridiza-
tion (aCGH) has shown mono and biallelic deletion of A20
in significant proportion of SS samples and its restoration
retarded cell cycle progression, while knockdown of A20 in
normal T cells promoted proliferation suggesting a tumor
suppressor role of A20 in T-cell malignancy (141). Apart
from its well-characterized role in inhibiting NFjB signal-
ing, A20 also regulates other cellular signaling circuits
including the Wnt pathway, the autophagic response and
the interferon regulatory factor (IRF) pathway (142–146).
Considering the genetic aberrations of A20 associated with
several hematologic malignancies and its role in the regula-
tion of diverse cellular signaling including inhibition of
NFjB signaling, apoptosis, and inflammation, future studies
involving the regulatory mechanisms of A20 and its ubiqu-
itin modulating activity on novel substrates might provide
opportunities for therapeutic interventions in A20 dysregu-
lated hematologic neoplasms.
Therapeutic opportunities and current clinical trials
targeting UPS in hematologic malignancies
The proteasome subunits are overexpressed in hematologic
malignancies. Notably, neoplastic cells of hematopoietic ori-
gin are significantly more sensitive to proteasomal inhibition
by lactacystin as compared to their normal counterparts
indicating the critical role UPS plays in hematopoietic neo-
plasia (147–150). Inhibition of the proteasome was
reported to result in largely selective apoptosis in patient-
derived lymphoma and leukemia cells, while considerably
sparing the untransformed cells. Hence, several proteasome
inhibitors with different mechanisms of action are currently
in several stages of clinical trials for different subsets of
lymphoma/leukemia.
Proteasome inhibitors currently in clinical trial
Bortezomib
A proteasome inhibitor that has had huge impact on treat-
ment of hematologic malignancy is bortezomib (VelcadeTM,
Millennium: the Takeda Oncology Company, Cambridge,
Massachusetts) (46, 47, 151). Bortezomib is the first FDA
approved proteasome inhibitor now used as a frontline
treatment for newly diagnosed multiple myeloma (MM),
relapsed/refractory MM, and mantle cell lymphoma. Less
efficacious but nevertheless encouraging responses have also
been observed in DLBCL and follicular lymphoma patients
(152). The major cellular machinery for proteolytic process-
ing is the 26S proteasome, an ATP-dependent complex com-
prised of a 20S catalytic core subunit and 19S regulatory
subunits (153). The 20S proteasome subunit is responsible
for the degradation of ubiquitinated substrates. Bortezomib
inhibits this machinery by reversibly binding to active site
of 20S proteasome. Bortezomib has shown notable success
in the treatment of MM and MCL, but it is not a perfect
drug. It is an unstable compound that retains activity only
within 4–8 h of reconstitution, and its therapeutic window
is narrow (154). Above its therapeutic dosage (1.3 mg/m2
body surface) and even at 1.5 mg/m2, it produces toxicity
that includes myelosuppression which leads to anemia, neu-
tropenia, and thrombocytopenia, and neuropathy, which
occurs in more than 30% patients (154). Furthermore, resis-
tance to bortezomib treatment is an emerging issue empha-
sizing the requirement for the development of second
generation inhibitors. To this end, several promising novel
proteasomal inhibitors have been developed and character-
ized in vitro, in vivo, and in clinical settings. Compared to
bortezomib, these agents are highly selective and irreversible
proteasomal inhibitors.
Carfilzomib
Carfilzomib, or PR171, is a proteasome inhibitor consisting
of a tetrapeptide epoxyketone. Carbilzomib irreversibly
binds to the b5 subunit of the 20S proteasome, resulting in
inhibition of the chymotrypsin-like activity. In July 2012,
the FDA approved carfilzomib for the treatment of MM
patients who have received at least two prior therapies
including bortezomib and an immunomodulatory agent
(IMID) and have shown disease progression within 60 days
of completion of the last therapy. Preclinical studies demon-
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strated that carfilzomib was active against bortezomib-resis-
tant multiple myeloma cell lines (155).
Marizomib
Marizomib (NPI-0052 or salinosporamide A) is a b-lactone-
c lactam structure containing natural proteasomal inhibitor
extracted from actinomycetes Salinispora tropica (156). Unlike
bortezomib, marizomib irreversibly binds to the proteasome
and inhibits the three major enzymatic activities (chymo-
trypsin-, trypsin-, and caspase-like). As compared to bort-
ezomib, marizomib showed improved therapeutic efficacy
in hematologic malignancy including activity on bortezo-
mib-resistant MM. In addition to MM, the therapeutic effi-
cacy of marizomib was also examined in MCL,
Waldenstrom’s macroglobulinemia (WM), chronic and
acute lymphocytic leukemia. Interestingly, marizomib in
combination with various histone deacetylase (HDAC)
inhibitors induced greater levels of cell death than the com-
binations of HDAC inhibitors and bortezomib (157, 158).
Orally active proteasome inhibitors
Technical challenges and cost effectiveness issues associated
with administration of bortezomib compelled researchers to
search for orally administered proteasomal linhibitors that
can be utilized or therapeutic approaches.
Ixazomib
Ixazomib (MLN 9708) is the first reversible oral proteasome
inhibitor to enter clinical investigation (159). Ixazomib is
administered as a stable citrate ester (ixazomib citrate) that
under physiological conditions rapidly hydrolyses to ixazo-
mib. It preferentially inhibits the chymotrypsin- like site of
the 20S proteasome. However, at higher concentrations, it
also inhibits the caspases-like and trypsin-like proteolytic sites.
Ixazomib inhibits growth and stimulates apoptosis in MM
cells that are resistant to conventional and bortezomib thera-
pies, while normal cells are relatively spared from toxicity.
Oprozomib
Oprozomib (ONX0912), is an orally bioavailable epoxyke-
tone-based proteasome inhibitor and like carfilzomib, inhib-
its the chymotrypsin-like activity of the proteasome and
induces cell death in myeloma cell lines and primary cells
from MM patients without appreciable cytotoxicity in nor-
mal hematopoietic cells (160). Oprozomib treatment is
effective in patients who relapsed after treatment with bort-
ezomib, dexamethasone, or lenalidomide.
Delanzomib
Delanzomib (CEP-18770) is a novel orally active inhibitor of
the chymotrypsin like activity of the proteasome. This drug
has advanced to phase 1 clinical trial for non-Hodgkin’s lym-
phoma (161). Like bortezomib, delanzomib is a reversible
proteasomal inhibitor. Initial studies using delanzomib have
shown a greater and more sustained dose-dependent inhibi-
tion in primary MM plasma cells in vitro (162).
Conclusions and future perspective
The controlled degradation of cell regulatory substrates
involved in cell cycle progression, cell cycle checkpoint,
response to genotoxic stress, signaling pathways, and tran-
scriptional control of gene expression is prerequisite for nor-
mal cellular homeostasis. In this context, the UPS plays a
vital role through precise temporal and context specific deg-
radation of regulatory proteins. Deregulation of the UPS in
hematopoietic cells results in complex outcomes contribut-
ing to the pathogenesis of hematopoietic malignancies.
However, inhibition of the proteasome system is expected
to accumulate the levels of hundreds of proteins regardless
of their role in cellular physiology and consequently kill
normal cells along with cancer cells. The activity of the
ubiquitination cascade comprising the E1, E2, and E3
enzymes is counteracted by the activity of the DUBs. Among
the three enzymes in the cascade, the E3 ubiquitin ligases
control a remarkable diversity of substrates with utmost
specificity. Hence, it is not surprising that these E3 ligases
are deregulated by multiple mechanisms ensuing aberrant
cellular response through their substrate abundance leading
to the development and progression of hematologic malig-
nancies. Although E3 ligases have been implicated in regula-
tion of diverse array of substrates, the understanding of the
subcellular location, context, and co-factors that dictate the
degradation of these substrates at particular physiologic or
pathologic states of cells is far from complete. A goal of
studying E3 ligase-mediated control of substrates regulating
critical cellular processes is to develop a therapeutic interven-
tion against aberrant activity of these ligases in cancer con-
texts. A notable advance in this arena is the FDA approval of
bortezomib (a general proteasome inhibitor) and use of
neddylation inhibitor (MLN4924) in clinical management of
various cancers. However, the strategy of inhibition of the
proteasomal apparatus carries unwanted complications and
lined to harmful effects on normal cells. Thus, there is an
exquisite need for effective regulators of E3 ligases that tar-
get specific cellular substrates in efficacious formulations and
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with minimal side effects. Such agents may plausibly be
alternatives or adjunctive to other currently existing effective
cancer therapeutics. Also noteworthy are the counteracting
activities of DUBs that balance the turnover of critical cellu-
lar regulators mediated by ubiquitination-driven proteasomal
degradation. Hence, aberrant expression and activity of
deubiqutinases also contribute to blood cancer. For example,
USP9X is overexpressed in leukemia and MM cells. To this
end, a small molecule inhibitor WP110 has been identified
as a partly selective DUB inhibitor that directly inhibit the
activity of USP9x, USP5, USP14, and UCH37 (163, 164).
These DUBs are known to regulate survival protein’s stability
and 26S proteasome function. However, knowledge on role
of different DUBs in hematologic neoplasms and their target
substrates as well as their mechanisms of action is quite lim-
ited and requires further exploration.
The preponderance of evidence implicates aberrant prote-
asomal degradation machinery as strongly contributing or
driving the evolution of several hematologic malignancies.
Furthermore, the extent to which post-translational modifi-
cations (phosphorylation, methylation, acetylation, or ubiq-
uitylation) influence the turnover of substrates through the
proteasomal machinery remains to be determined. Presently,
several laboratories are utilizing state-of-the-art tools includ-
ing next generation sequencing and advanced proteomic
approaches to identify structural alterations that subvert nor-
mal proteolytic degradation of critical substrates involved in
hematopoietic homeostasis. Further, in vivo experimental
models are being developed to provide a more sophisticated
understanding of the deregulated UPS pathway in hemato-
logic neoplasia. Continued efforts in this arena worldwide
are anticipated to reveal insights that will facilitate better
understanding of contribution of the UPS to the develop-
ment of hematologic malignancies and elucidate novel ave-
nues for the development of novel treatments for
hematopoietic neoplasms.
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